ES
MARKETS / NASDAQ / SIGA
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Siga Technologies, Inc. SIGA

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$94.6M
▼ 31.8% vs FY2024
EPS · FY25
$0.32
Dividend / sh · FY25
$0.60
Payout · FY25
185%
ROE · FY25
11.2%
Net margin · FY25
24.6%
Dividend coverage
0.5×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 94.6M
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.20.40.60.10.02009201220152018202120242025
0.20.40.60.10.02016201920222025

25 cents of every revenue dollar became profit this year.

Per share
USD 0.32
Diluted EPS, FY2025
EPS Dividend
2460.600.322009201220152018202120242025
2460.600.322016201920222025

Earnings covered only a fraction of the dividend — the rest came from cash or borrowing.

Profitability
11.2%
Return on equity, FY2025
ROE
8016024011.2%2009201220152018202120242025
8016024011.2%2016201920222025
Operating margin25.1%
Net margin24.6%
Return on assets10.0%

Each USD of equity produced 11 cents of profit this year.

Returned to shareholders
USD 43.1M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 43.1M
Net buybacksUSD 0.00
Share of profit185.2%
Consecutive raises—

USD 43.1M in dividends — 185% of the year's profit, so the payout drew on cash built up earlier.

Growth
−5.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−5.1%
−5.4%
Net income
−11.8%
−16.2%
EPS, diluted
−11.4%
−14.7%
Dividend / share
+10.1%
Returned to shareholders
−2.1%
+8.6%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.07B
Shares outstanding, FY2025
0.050.072009201220152018202120242025
0.080.072016201920222025
Change, 5 years−7.2%
Change, 10 years−9.0%

The share count shrank 7% in five years — the same company, cut into fewer, larger slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 219.5M
total assets, end of FY2025
Total assetsUSD 219.5M
EquityUSD 198.8M
CashUSD 155.0M
Current ratio11.83×

Equity funds 91% of total assets.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.5
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
0.0
0.1
0.1
0.0
0.1
0.1
−0.0
0.4
−0.0
−0.0
−0.0
−0.2
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.1
0.1
0.0
0.1
0.1
−0.0
0.4
−0.0
−0.0
−0.0
−0.2
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.1
−0.0
−0.0
−0.0
0.0
0.0
Net income $B
0.0
0.1
0.1
0.0
0.1
0.1
−0.0
0.4
−0.0
−0.0
−0.0
−0.3
−0.0
−0.0
0.0
−0.1
−0.0
EPS, diluted $
0.32
0.82
0.95
0.46
0.91
0.71
−0.15
5.18
−0.46
−0.69
−0.73
−4.97
−0.33
−0.27
0.09
−1.12
−0.52
Dividend / sh $
0.60
0.60
0.45
0.45
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
185
72
47
97
0
0
·
·
·
·
·
·
·
·
·
·
·
ROE %
11.2
28.7
37.1
19.7
45.7
49.5
−7.2
·
·
·
·
·
−76.0
−40.7
208.9
·
·
Shares out B
0.07
0.07
0.07
0.07
0.07
0.08
0.08
0.08
0.08
0.08
0.08
0.05
0.05
0.05
0.05
0.05
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed